Tumor ischemia induction via arterial embolization

Tumor ischemia induction via arterial embolization is not a molecular target or receptor but rather a **therapeutic procedure** used primarily in interventional oncology. The technique involves the selective occlusion of arteries supplying blood to a tumor using various embolic materials such as particles, coils, gels, or liquid agents. This process deprives the tumor tissue of oxygen and nutrients by blocking its blood supply—leading to **tumor cell death through ischemia and necrosis**[2][4]. In some cases—such as transcatheter arterial chemoembolization (TACE)—the procedure also delivers chemotherapeutic drugs directly into the tumor's vasculature for enhanced local cytotoxicity[3]. Arterial embolization is most commonly applied to treat unresectable solid tumors like hepatocellular carcinoma and adrenal tumors when surgery is not feasible. It can be performed alone ("bland" or "TAE") or combined with chemotherapy ("chemoembolization") or radiotherapy ("radioembolization")[1][2][3]. The choice of agent depends on clinical context and operator preference. Because "tumor ischemia induction via arterial embolization" refers to a **procedure**, not a discrete molecule/receptor/target protein/gene/family**, it should not be classified as a canonical therapeutic target. Therefore: > There is something wrong with this target entry—it describes an interventional technique rather than an individual molecular entity. References supporting these statements include reviews on adrenal artery/liver artery embolizations and technical descriptions from cancer treatment guidelines[1][2][3][4].

Other names

Arterial embolizationTrans-arterial embolizationTAETumor arterial embolizationEmbolization therapy for tumors

Induction of tumor ischemia by blocking arterial blood supply[2][4] Delivery of cytotoxic agents directly to the tumor (in chemoembolization)[3]